1.Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.
Jeongshim LEE ; Sung Soo AHN ; Jong Hee CHANG ; Chang Ok SUH
Yonsei Medical Journal 2018;59(2):194-201
PURPOSE: To evaluate the adequacy of retreatment, including hypofractionated re-irradiation (HFReRT), after surgery for recurrent glioblastoma (GBM) and related prognosticators of outcomes. MATERIALS AND METHODS: From 2011 to 2014, 25 consecutive patients with recurrent (n=17) or secondary (n=7) disease underwent maximal surgery and subsequent HFReRT after meeting the following conditions: 1) confirmation of recurrent or secondary GBM after salvage surgery; 2) Karnofsky performance score (KPS) ≥60; and 3) interval of ≥12 months between initial radiotherapy and HFReRT. HFReRT was delivered using a simultaneous integrated boost technique, with total dose of 45 Gy in 15 fractions to the gross tumor volume (GTV) and 37.5 Gy in 15 fractions to the clinical target volume. RESULTS: During a median follow-up of 13 months, the median progression-free and overall survival (OS) were 13 and 16 months, respectively. A better KPS (p=0.026), no involvement of the eloquent area at recurrence (p=0.030), and a smaller GTV (p=0.005) were associated with better OS. Additionally, OS differed significantly between risk groups stratified by the National Institutes of Health Recurrent GBM Scale (low-risk vs. high-risk, p=0.025). Radiologically suspected radiation necrosis (RN) was observed in 16 patients (64%) at a median of 9 months after HFReRT, and 8 patients developed grade 3 RN requiring hospitalization. CONCLUSION: HFReRT after maximal surgery prolonged survival in selected patients with recurrent GBM, especially those with small-sized recurrences in non-eloquent areas and good performance.
Adult
;
Brain Neoplasms/mortality/pathology/*therapy
;
Dose Hypofractionation
;
Female
;
Glioblastoma/mortality/pathology/*therapy
;
Humans
;
Karnofsky Performance Status
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/mortality/pathology/*therapy
;
Prognosis
;
*Radiosurgery
;
Re-Irradiation/*methods
;
Salvage Therapy/methods
;
Survival Rate
;
Treatment Outcome
2.Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.
Eun Kyoung LEE ; Seung Hong CHOI ; Tae Jin YUN ; Koung Mi KANG ; Tae Min KIM ; Se Hoon LEE ; Chul Kee PARK ; Sung Hye PARK ; Il Han KIM
Korean Journal of Radiology 2015;16(6):1341-1348
OBJECTIVE: To determine whether histogram values of the normalized apparent diffusion coefficient (nADC) and normalized cerebral blood volume (nCBV) maps obtained in contrast-enhancing lesions detected on immediate post-operative MR imaging can be used to predict the patient response to concurrent chemoradiotherapy (CCRT) with temozolomide (TMZ). MATERIALS AND METHODS: Twenty-four patients with GBM who had shown measurable contrast enhancement on immediate post-operative MR imaging and had subsequently undergone CCRT with TMZ were retrospectively analyzed. The corresponding histogram parameters of nCBV and nADC maps for measurable contrast-enhancing lesions were calculated. Patient groups with progression (n = 11) and non-progression (n = 13) at one year after the operation were identified, and the histogram parameters were compared between the two groups. Receiver operating characteristic (ROC) analysis was used to determine the best cutoff value for predicting progression. Progression-free survival (PFS) was determined with the Kaplan-Meier method and the log-rank test. RESULTS: The 99th percentile of the cumulative nCBV histogram (nCBV C99) on immediate post-operative MR imaging was a significant predictor of one-year progression (p = 0.033). ROC analysis showed that the best cutoff value for predicting progression after CCRT was 5.537 (sensitivity and specificity were 72.7% and 76.9%, respectively). The patients with an nCBV C99 of < 5.537 had a significantly longer PFS than those with an nCBV C99 of ≥ 5.537 (p = 0.026). CONCLUSION: The nCBV C99 from the cumulative histogram analysis of the nCBV from immediate post-operative MR imaging may be feasible for predicting glioblastoma response to CCRT with TMZ.
Adult
;
Aged
;
Antineoplastic Agents, Alkylating/*therapeutic use
;
Brain/pathology/radiography
;
Brain Neoplasms/*drug therapy/mortality/radiography
;
Chemoradiotherapy
;
Dacarbazine/*analogs & derivatives/therapeutic use
;
Diffusion Magnetic Resonance Imaging
;
Disease Progression
;
Disease-Free Survival
;
Female
;
Glioblastoma/*drug therapy/mortality/radiography
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Proportional Hazards Models
;
ROC Curve
;
Retrospective Studies